07 August 2010
The protective action of topiramate on dopaminergic neurons
Shengming HuangABCDEF, Haizhen WangABCDEF, Yuming XuDE, Xinyu ZhaoDF, Junfang TengACD, Yunhan ZhangADEMed Sci Monit 2010; 16(9): BR307-312 :: ID: 881122
Abstract
Background: The present study analyzed the neuroprotective effects of topiramate on 6-hydroxydopamine (6-OHDA)–induced toxicity in primary dopaminergic mesencephalic neuronal cell cultures.
Material/Methods: Through the use of tyrosine hydroxylase and microtubule-associated protein 2 immunocytochemistry, the morphology and development of dopaminergic neurons was observed. Hoechst33258 and propidium iodide (PI) double staining was used to determine cell membrane penetrability and apoptosis by fluorescent microscopy. Methyl thiazole tetrazolium was used to assay cell viability and metabolism. The cells were assigned to 3 groups: (1) control: primary cultured neurons; (2) 6-OHDA: primary cultured neurons and 6-OHDA; and (3) topiramate (TPM) protection: primary cultured neurons and 6-OHDA, treated with various concentrations (10, 50, and 100 µM) of TPM.
Results: Hoechst 33258 and PI double immunofluorescence revealed that the number of dying cells after 6-OHDA treatment was greater than after TPM treatment. Compared with the 6-OHDA group, there were more neurons with greater cell viability in the 6-OHDA plus TPM group.
Conclusions: Topiramate was shown to provide protection to dopaminergic neurons exposed to 6-OHDA by reducing cell apoptosis and enhancing cell viability. The neuroprotective effects of TPM were dose-dependent.
Keywords: Propidium - metabolism, Neuroprotective Agents - pharmacology, Neurons - metabolism, Microtubule-Associated Proteins - metabolism, Fructose - pharmacology, Formazans - metabolism, Fluorescent Antibody Technique, Dopamine - metabolism, Cell Shape - drug effects, Cell Proliferation - drug effects, Cell Death - drug effects, Cell Count, Bisbenzimidazole - metabolism, Staining and Labeling, Tetrazolium Salts - metabolism, Tyrosine 3-Monooxygenase - metabolism
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952